60 Afatinib in EGFR mutation positive advanced non-small cell lung cancer

Davies, Rhian Siân; Brewster, Abenaa; Button, M.; Lester, J.F.

doi:10.1016/s0169-5002(16)30077-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This shows that afatinib targeted therapy can effectively improve the immune function of patients and reduce its adverse reactions. The reason for the analysis is that afatinib targeted therapy is an important molecule acting on the signaling pathway, which can effectively hinder the expansion of malignant tumor lesions and improve the patient's immune response ability, thereby improving their immune function and reducing adverse reactions [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC)

Cao

Jiang

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Objective. This study is aimed at investigating the clinical intervention effect of afatinib targeted therapy in patients with non-small-cell lung cancer. Methods. The research object was a retrospective analysis of 86 patients with non-small-cell lung cancer who were admitted to our hospital from 1st January 2019 to 31st December 2021. The patients were divided into two groups. The patients in the two groups received conventional chemotherapy intervention, and the patients in group B received afatinib targeted therapy intervention on the basis of the treatment in group A. The clinical intervention effect, immune function, serum EGFR level, serum pro-GRP level, and incidence of adverse reactions were compared between the two groups of patients. Results. After afatinib targeted therapy intervention, the total intervention effective rate of patients in treatment group B was significantly higher than that in patients in treatment group A. Compared with the treatment group A, the CD3+, CD4+, CD8+, and CD4+/CD8+ of the treatment group were significantly upregulated. After the intervention, the serum EGFR levels of patients in treatment groups A and B were significantly decreased, and the serum EGFR levels in patients in treatment group B were significantly lower than those in patients in treatment group A. The serum pro-GRP level in group B patients was significantly decreased. The overall incidence of adverse reactions in treatment group B was significantly lower than that in treatment group A. Conclusion. Afatinib targeted therapy has a significant clinical intervention effect on patients with non-small-cell lung cancer, which not only helps to improve the immune function of patients but also effectively improves the serum EGFR and pro-GRP levels of patients.

show abstract

Section: Discussionmentioning

confidence: 99%